{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:01:06Z","timestamp":1783720866530,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":140,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.rmcr.2025.102237","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:19:07Z","timestamp":1747927147000},"page":"102237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-087X","authenticated-orcid":false,"given":"Shota","family":"Kaburaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kamio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.rmcr.2025.102237_bib1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2025.102237_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2022.07.014","article-title":"Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure","volume":"174","author":"Yoon","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.rmcr.2025.102237_bib3","article-title":"Lung toxicity occurring during enfortumab vedotin treatment: from a priming case report to a retrospective analysis","volume":"17","author":"Desimpel","year":"2024","journal-title":"Pharmaceuticals (Basel) [Internet]"},{"issue":"10","key":"10.1016\/j.rmcr.2025.102237_bib4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.rmcr.2025.102237_bib5","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.rmcr.2025.102237_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"10","key":"10.1016\/j.rmcr.2025.102237_bib7","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.rmcr.2025.102237_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","article-title":"Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of nectin-4-expressing cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"issue":"102378","key":"10.1016\/j.rmcr.2025.102237_bib9","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.rmcr.2025.102237_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmcr.2025.102237_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.rmcr.2025.102237_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.rmed.2012.09.021","article-title":"CD4+ and CD8+ T lymphocytes in lung tissue of NSIP: correlation with T lymphocytes in BALF","volume":"107","author":"Qin","year":"2013","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmcr.2025.102237_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09674845.2008.11732798","article-title":"Differences in lymphocyte profile between BAL fluid and human lung tissue from patients with interstitial lung disease","volume":"65","author":"Fujimori","year":"2008","journal-title":"Br. J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.rmcr.2025.102237_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1513\/AnnalsATS.202102-198OC","article-title":"Transbronchial lung cryobiopsy in patients with interstitial lung disease: a systematic review","volume":"19","author":"Kheir","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"10.1016\/j.rmcr.2025.102237_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J. Clin. Med."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125000735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007125000735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T11:45:31Z","timestamp":1751629531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007125000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":15,"alternative-id":["S2213007125000735"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102237","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2025.102237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102237"}}